GlassScriptPhysician profile
Ann M Padilla
NPI 1790705598
$3,391.61
in general payments reported to CMS, 2019-2025
37 companies · $585 in 2025
The $585 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $388 · 2020: $99.16 · 2022: $570 · 2023: $920 · 2024: $829 · 2025: $585.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,234 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,234.10 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $846.96 | 2019-2025 | |
| Astellas Pharma US INC | $314.81 | 2019-2025 | Veozah |
| Lilly USA, LLC | $311.52 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $234.88 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $230.35 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Dexcom, INC. | $129.96 | 2023-2025 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $115.10 | 2022-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| Amgen INC. | $105.87 | 2019-2025 | Evenity, Krystexxa, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $84.44 | 2019-2022 | |
| Glaxosmithkline, LLC. | $83.45 | 2023 | Shingrix, Arexvy, Trelegy Ellipta |
| Radius Health, INC. | $81.60 | 2024-2025 | Tymlos |
| Novo Nordisk INC | $71.99 | 2020-2024 | |
| Currax Pharmaceuticals LLC | $71.02 | 2024 | Contrave |
| Gilead Sciences, INC. | $50.87 | 2022-2023 | Epclusa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.28 | 2022-2025 | Jardiance |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ann Padilla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.